Literature DB >> 27307378

Increased neuronal seizure activity correlates with excessive systemic inflammation in a rat model of severe preeclampsia.

Lei Liu1, Xinjia Han1, Qian Huang1, Xiaoqin Zhu2, Jinying Yang1, Huishu Liu1.   

Abstract

Preeclampsia (PE), one of the most common disorders of pregnancy, is characterized by hypertension and albuminuria. In severe cases, PE results in eclampsia-like seizures. Studies have suggested that severe PE is related to an exaggerated systemic inflammatory response, which may increase sensitivity to seizures. In the current study, we investigated whether the seizure activity of neurons was enhanced under excessive systemic inflammation. We also sought to determine whether MgSO4 could reduce the effects of systemic inflammation on seizure activity after electrical stimulation in a lipopolysaccharide (LPS)-induced model of PE. In addition to pregnancy outcomes, we analyzed biochemical parameters to ascertain whether our PE model was successful. Enzyme-linked immunosorbent assay analysis revealed that the levels of inflammatory cytokines (tumor necrosis factor (TNF)-α and interleukin (IL)-1β) were significantly higher in the LPS-treated rats than in the untreated rats. After electrical stimulation, behavioral assessments showed that the LPS-treated rats that were not treated with MgSO4 had the shortest latency period to develop a seizure and the longest seizure duration. The electroencephalographic (EEG) recordings in the hippocampus demonstrated that this group also had the highest EEG amplitude. MgSO4 treatment significantly decreased both TNF-α and IL-1β concentrations, increased the latency to develop a seizure, decreased the seizure duration and shortened the EEG amplitude. These results suggest that neuronal seizure activity and systemic inflammation are increased in severe PE. In addition, MgSO4 treatment reduced systemic inflammation and seizure severity. We conclude that excessive systemic inflammation in PE promotes eclampsia seizures, which can be attenuated by MgSO4 treatment.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27307378     DOI: 10.1038/hr.2016.53

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  6 in total

1.  Description of a strong relationship among total cell-free DNA levels, LDH values, AST values and platelet count in patients with HELLP syndrome.

Authors:  Pablo Stiefel; María L Miranda; Hada Macher; Luis M Beltran-Romero; Rocio Muñoz-Hernandez
Journal:  Hypertens Res       Date:  2017-03-23       Impact factor: 3.872

2.  Magnesium Sulfate Provides Neuroprotection in Eclampsia-Like Seizure Model by Ameliorating Neuroinflammation and Brain Edema.

Authors:  Xiaolan Li; Xinjia Han; Jinying Yang; Junjie Bao; Xiaodan Di; Guozheng Zhang; Huishu Liu
Journal:  Mol Neurobiol       Date:  2016-11-22       Impact factor: 5.590

3.  Effect of blood pressure on reversible posterior leukoencephalopathy syndrome in pre-eclampsia or eclampsia.

Authors:  Fang Xiaobo; Liang Yanling; Chen Dunjin; He Fang; Chen Jia; Zhong Yuhua; Zhang Weixi
Journal:  Hypertens Res       Date:  2017-11-02       Impact factor: 3.872

4.  Cyclosporin A ameliorates eclampsia seizure through reducing systemic inflammation in an eclampsia-like rat model.

Authors:  Qian Huang; Bihui Hu; Xinjia Han; Jinying Yang; Xiaodan Di; Junjie Bao; Huishu Liu
Journal:  Hypertens Res       Date:  2020-01-14       Impact factor: 3.872

5.  Changes in the Expression of AQP4 and AQP9 in the Hippocampus Following Eclampsia-Like Seizure.

Authors:  Xinjia Han; Qian Huang; Lei Liu; Xiaoyan Sha; Bihui Hu; Huishu Liu
Journal:  Int J Mol Sci       Date:  2018-01-19       Impact factor: 5.923

6.  Prenatal intake of omega-3 promotes Wnt/β-catenin signaling pathway, and preserves integrity of the blood-brain barrier in preeclamptic rats.

Authors:  Asmaa M ShamsEldeen; Marwa Nagi Mehesen; Basma Emad Aboulhoda; Laila Ahmed Rashed; Mohamed Mahmoud Elsebaie; Enas Ahmed Mohamed; Maha Mohammed Gamal
Journal:  Physiol Rep       Date:  2021-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.